Print Page | Contact Us | Report Abuse | Sign In | Register
Effectively Engaging and Treating Individuals with Opioid Use Disorders - Opioid Summit Day 2
Tell a Friend About This EventTell a Friend
Effectively Engaging and Treating Individuals with Opioid Use Disorders - Opioid Summit Day 2

 Export to Your Calendar 9/29/2020
When: Tuesday September 29, 2020
1:00 pm - 4:00 pm
Where: United States

« Go to Upcoming Event List  

DAY 2 – September 29, 2020

1:00 pm Welcome
1:05 pm Retaining Patients in Treatment
  • Florida Data
1:20 pm Engagement & Retention Strategies
  • MAT for Opioid Use Disorder: Innovative Models for Enhancing Retention and Continuity of Care
2:30 pm Retention Strategies Across Florida Discussion
3:10 pm Treating Stimulants
3:45 pm Future Action
4:00 pm Adjourn


Medication-Assisted Treatment for Opioid Use Disorder: Innovative Models for Enhancing Retention and Continuity of Care

Evidence-based treatments for opioid use disorder (OUD) include medication-assisted treatment (MAT) or medication for opioid use disorder (M/OUD). Retention in MAT results in better outcomes; yet, rates of treatment retention are low. This presentation discusses the results of a study conducted for the Assistant Secretary for Planning and Evaluation that examined models and strategies for retaining individuals in treatment and for enhancing continuity of care across settings. Among the settings examined were geographically diverse opioid treatment programs; specialty and non-specialty providers of buprenorphine; home-delivery of injectable naltrexone; a provider offering a spectrum of SUD, mental and physical health care, and housing and employment services; and a large health system working closely with the criminal justice system. The presentation highlights practical lessons learned that the audience may find useful to adapt for their particular service settings.

Presentation Objectives:

  1. Describe innovative approaches to enhancing retention in medication treatment for opioid use disorder
  2. Assess treatment practices that may impede retention and continuity of care
  3. Apply techniques to promote retention in treatment



Peggy O’Brien, PhD, JD, is a Senior Research Leader at IBM Watson Health. Dr. O’Brien is a behavioral health services researcher, with subject matter expertise in mental and substance use disorder service delivery, utilization, and financing. Much of her recent research for federal agencies has focused on the opioid crisis, including opioid prescribing practices and policies; the prevalence of polysubstance use and co-occurring conditions with opioid use disorder; the delivery of medication treatment for alcohol and opioid use disorders (M/AUD, M/OUD); initiation, engagement, continuity of care and retention in M/OUD; the use of telehealth in the treatment of substance use disorders; and the regulatory structure supporting use of residential treatment for substance use and mental health disorders. Dr. O’Brien also has done work in furtherance of the SUPPORT Act, including related to increased capacity for M/OUD treatment and Medicaid funding of housing supports for individuals who are homeless and who have substance use disorders.

Dr. O’Brien previously worked as an attorney and as a mental health clinician. She was the Clinical Director of a secure residential facility in Massachusetts that treats adolescents with co-occurring serious emotional disturbance and intellectual disabilities. Dr. O’Brien received her PhD in social policy and management with a concentration in behavioral health services from the Heller School of Social Policy and Management at Brandeis University where she was a National Institute of Alcohol Abuse and Alcoholism trainee.